Background: Nodular regenerative hyperplasia is an uncommon liver condition associated with several autoimmune disorders and drugs. The clinical symptoms of nodular regenerative hyperplasia vary from asymptomatic to severe complications of portal hypertension (nodular regenerative hyperplasia-syndrome).
Objective: The purpose of this study was to identify the prognosis and optimal management, as well as the role of liver transplantation, in nodular regenerative hyperplasia.
Methods: The pathology databases of all three Dutch liver transplant units were retrospectively scrutinised for explanted livers diagnosed with nodular regenerative hyperplasia or without clear diagnosis. Pre- and post-transplantation clinical, biochemical, radiological and histological information was obtained from electronic and paper records.
Results: In total, 1886 patients received a liver transplant. In 255 patients, nodular regenerative hyperplasia could not be excluded. After detailed chart review, the native livers of 11 patients (0.6%) (82% male, median age: 44 years) displayed nodular regenerative hyperplasia. Seven patients (64%) had underlying disorders or drug exposure which possibly caused nodular regenerative hyperplasia. Laboratory and imaging abnormalities were present in all patients but did not contribute to the diagnosis of nodular regenerative hyperplasia. Five-year survival was 73% (median follow-up: four years, range: 2-248 months).
Conclusion: Nodular regenerative hyperplasia is a rare finding in patients, predominantly young males, transplanted for end-stage liver disease with unknown aetiology. Nonetheless, liver transplantation may have an important role in end-stage nodular regenerative hyperplasia-syndrome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548351 | PMC |
| http://dx.doi.org/10.1177/2050640616680550 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nodular Regenerative Hyperplasia: Report of 82 Patients and Systematic Review of Literature.
United European Gastroenterol J
December 2024
Department of Gastroenterology and Hepatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Background: Data about the clinical significance and outcome of patients with nodular regenerative hyperplasia are limited.
Objective: The aim of this study was to describe the clinical and histopathological characteristics of patients with nodular regenerative hyperplasia and compare our findings with the literature.
Methods: From January 2015 to March 2021, patients with a diagnosis of nodular regenerative hyperplasia were included.
The histological grading of fibrosis in Budd-Chiari syndrome: A chronic liver disease, different from others.
Indian J Gastroenterol
November 2024
Department of Biostatistics and Health Informatics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, 226 014, India.
Introduction: Budd-Chiari syndrome (BCS) is an uncommon disease caused by hepatic venous outflow obstruction. They can result in centrilobular fibrosis, nodular regenerative hyperplasia and cirrhosis. Assessing liver fibrosis is crucial for determining the stage of BCS, predicting disease progression and guiding treatment decisions.
View Article and Find Full Text PDFNon-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management.
Hepatol Int
December 2024
Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
Since the Asian Pacific Association for the Study of the Liver (APASL) published guidelines on non-cirrhotic portal fibrosis/idiopathic portal hypertension in 2007, there has been a surge in new information, especially with the introduction of the term porto-sinusoidal vascular disorder (PSVD). Non-cirrhotic intra-hepatic causes of portal hypertension include disorders with a clearly identifiable etiology, such as schistosomiasis, as well as disorders with an unclear etiology such as non-cirrhotic portal fibrosis (NCPF), also termed idiopathic portal hypertension (IPH). This entity is being increasingly recognized as being associated with systemic disease and drug therapy, especially cancer therapy.
View Article and Find Full Text PDFHepatopulmonary syndrome associated with long-term use of ado-trastuzumab emtansine (T-DM1) for treatment of HER2-positive metastatic breast cancer - a case report and series.
Front Oncol
October 2024
Department of Oncology, Mayo Clinic, Rochester, MN, United States.
Article Synopsis
- ADCs in Cancer Therapy
- : Antibody-drug conjugates (ADCs), like ado-trastuzumab emtansine (T-DM1), are a significant breakthrough in cancer treatment, specifically for HER2-positive breast cancer, allowing targeted delivery of drugs to tumor cells while sparing normal tissue, but they can cause severe toxicity requiring monitoring.
- Hepatopulmonary Syndrome (HPS) Cases
- : A case series of four patients who received T-DM1 revealed they developed hepatopulmonary syndrome (HPS), which involves severe respiratory issues and is linked to long-term liver damage caused by the drug.
- Need for Awareness
- : The findings underscore the importance of recognizing
Tubulointerstitial nephritis with IgM-positive plasma cells complicated by liver failure.
CEN Case Rep
October 2024
Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 14, Nishi 5, Kita-ku, Sapporo, 060-8648, Japan.
Tubulointerstitial nephritis (TIN) is characterized by inflammation of the renal interstitium with the infiltration of immune cells, mainly consisting of T cells. Recently, patients with TIN with the predominant infiltration of immunoglobulin M (IgM)-positive plasma cells were reported, coined IgMPC-TIN. Here we report the case of a 70-year-old woman diagnosed with Fanconi syndrome and renal tubular acidosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!